Mie Study of Clopidogrel Low Responder in Atherothrombotic Disease Patients with/without Diabetes
Not Applicable
- Conditions
- Atherothrombotic disease
- Registration Number
- JPRN-UMIN000001574
- Lead Sponsor
- McLORDD, Coordinating Office
- Brief Summary
CYP2C19 loss-of-function genotype is associated with more frequent high platelet reactivity, as assessed by ADP-specific platelet function tests, in Japanese patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients before operation 2) Cerebral infraction without embolization from the heart 3) Taking following drugs, warfarin, thrombolytic agents, heparin, etc. anti-platelet drugs except aspirin, clopidogrel or cilostazol (e.g., sarpogrelate, diryridamole, EPA, etc.) 4) Not eligible determind by the responding physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To develop the monitoring techniques of poor-responder for clopidgrel
- Secondary Outcome Measures
Name Time Method Relationship of SNIP of CYP2C19 Relationship of DM